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Abstract
Appropriate perioperative management of patients on chronic oral anticoagulation (OAC)—including warfarin and the direct oral
anticoagulants—is a poorly defined yet important clinical issue with potentially severe consequences in the postoperative period.
We sought to prospectively evaluate the effect of the Management of Anticoagulation in the Periprocedural Period (MAPPP)
mobile app as a clinical decision tool in the management of patients on chronic OAC undergoing elective procedures or surgeries.
Between January 1, 2018, and January 31, 2019, 642 patients treated in our health system were included. Eligible patients met the
following criteria: age >18 years old, creatinine clearance 15 mL/min, and on chronic OAC with adequate information regarding
baseline characteristics. Our study outcome was patient’s emergency department (ED) visits within 30 days postprocedure. The
MAPPP app was integrated into the electronic health record (EHR), and the end user was free to accept or decline recommended
evidence-based perioperative anticoagulation management guidance. Analysis revealed that acceptance was more common in
younger patients (P ¼ .0137), patients on oral anticoagulants other than warfarin (P < .0001), and patients undergoing increased
bleeding risk procedures (P ¼ .0068). Acceptance of the MAPPP app recommendation was significantly associated with fewer ED
visits (acceptance group: 4.0% vs rejection group: 8.3%, P ¼ .0205). Logistic regression showed that intervention acceptance and
female gender were significantly associated with fewer—while age 80 with more—30-day ED visits. Our findings indicate that
newer technologies, such as the MAPPP app, integrated into clinical EHR workflow, can significantly augment evidence-based
perioperative anticoagulation management and potentially result in a reduction of adverse outcomes.
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Introduction
The periprocedural management of patients receiving chronic
oral anticoagulants (OACs) such as vitamin K antagonists like
warfarin and direct oral anticoagulants (DOACs) represents an
important dilemma for practicing physicians and affects at least
250 000 patients/year in North America.1-3Annually, 1 out of
every 6 patients on chronic OAC with atrial fibrillation (AF)
require an elective surgical procedure and periprocedural anticoagulation interruption.4-6 The management of patients on
chronic OAC during the periprocedural period is complicated
by the conflicting risks of procedure-related bleeding or thrombosis associated with patient-related factors or interruption of
anticoagulant therapy, respectively. Previously, the Greater
Cincinnati/Northern Kentucky Stroke Study has shown that
5.2% of the 2197 first-ever or recurrent strokes occur after
withdrawal of anticoagulant or antiplatelet therapy, and
47.4% of discontinuation events occur in the periprocedural
period. The authors suggested the need for more careful clinical
decision approaches for the management of anticoagulation/
antiplatelet medications in the periprocedural period.7
The US Department of Health and Human Services’
National Action Plan for Adverse Drug Event Prevention (ADE
Action Plan) outlined opportunities to prevent anticoagulantrelated ADEs through innovations in the areas of surveillance,
use of evidence-based prevention tools, and utilization of
health informatics technology (HIT).8 In addition, according
to the ADE Action Plan, the likelihood for an ADE increases
during transitions of care, such as elective surgical procedures
that commonly interrupt the routine patient management
process. Health informatics technology includes mobile and
web-based health apps that augment the decision-making and
facilitate appropriate management of chronic diseases.9 In
2013, the New York State Anticoagulation Coalition guided
the development of the Management of Anticoagulation in the
Periprocedural Period (MAPPP) mobile app in order to facilitate clinician awareness and clinical decision support of the
most current guidelines of the periprocedural management of
patients on chronic OAC, including warfarin and DOACs. The
MAPPP app utilizes a 3  3 matrix to classify patients according to patient-related thromboembolic risk (low, moderate, or
high) and periprocedural bleeding risk (minimal, low, or high).
The resulting output includes evidence-based recommendations regarding periprocedural anticoagulation interruption and
timing, heparin bridging, and indicated laboratory monitoring,
as well as timing and dosing scheme of postoperative anticoagulant reinitiation.10
Our prospective cohort study evaluated the implementation
of the MAPPP app as a clinical decision support tool in the
periprocedural management of patients on chronic OAC (warfarin and DOACs) undergoing elective invasive procedures.
The primary intervention was the integration of MAPPP app
into active clinical decision support (CDS) within the electronic health record (EHR) of our health system. Targeted
application users included nurse practitioners responsible for
presurgical testing and physicians ordering surgical
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procedures. The primary objective of the present study was
to ascertain if use of the MAPPP app resulted in fewer postprocedural emergency department (ED) visits.

Methods
Study Design
An overview of the MAPPP app design and recommendations
based on a 3  3 matrix of procedural bleed risk (minimal, low,
and high) and patient-related thromboembolic risk (low, moderate, high) is shown in Supplementary Figure. The MAPPP
app was integrated in our health system’s Sunrise EHR (Allscripts) by using REDCap, an electronic data capture tool.
Health care practitioners’ participation in the project
required education and support for the MAPPP app through
our institution’s online learning module and a live continuing
medical education program. The end user was free to follow or
decline recommended evidence-based guidance, and 2 distinct
cohorts were created based on the acceptance or rejection of
MAPPP app recommendations by health care providers. Eligible patients met the following criteria: age >18 years old, creatinine clearance 15 mL/min (patients undergoing dialysis
were excluded), on chronic OAC treatment (warfarin, dabigatran, rivaroxaban, or apixaban), and adequate information
regarding grouping (acceptance or rejection group), date of
surgery, age, gender, weight, procedural bleeding risk, patient
thromboembolic risk, and medical record number (to identify
follow-up data in the EHR system). As per the MAPPP app
recommendations, procedural bleeding risk was classified as
“minimal,” “low,” and “high,” and patient-related thromboembolic risk was classified as “low,” “medium,” or “high.” In
addition, classification of patients included antiplatelet medication use in the form of aspirin or clopidogrel. This study was
reviewed and approved by the institutional review board at
Northwell Health.

Study Data and Outcomes
The primary outcome for the study was emergency department
visits within 30 days of the procedure (yes/no at the patient
level) identified using billing data. Baseline patient characteristics (age, gender, weight) and clinical parameters (creatinine,
creatinine clearance, anticoagulation medication, antiplatelet
medication, procedural bleeding risk, patient-related thromboembolic risk) were extracted from the EHR. Data collection
was facilitated through REDCap, both manually and through
direct REDCap acquisition of EHR structured fields.

Statistical Analysis
Data analysis was performed to compare patients’ demographics, the utilization of anticoagulant and antiplatelet medications, procedural bleeding and patient thromboembolic risk,
and 30-day postoperative ED visits. Bivariate analyses compared the acceptance and rejection groups as well as the with or
without 30-day ED visit groups. Continuous variables were
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Table 1. Patient Characteristics and Outcomes (N ¼ 642).
Patient characteristics
Age category
20-64
65-79
80þ
Gender
Male
Female
Weight (kg)
Creatinine (mg/dL)
Creatinine clearance (mL/min)
Anticoagulation medication
Warfarin
Dabigatran
Rivaroxaban
Apixaban
Antiplatelet medication
Aspirin
Yes
No
Clopidogrel
Yes
No
Procedure bleeding risk
Minimal
Low
High
Patient’s thromboembolic risk
Low
Medium
High
Intervention group
Acceptance
Rejection

Mean (SD)

n (%)
149 (23.2%)
288 (44.9%)
205 (31.9%)

86.7 (24.1)
1.23 (1.27)
76.4 (42.7)

369 (57.5%)
273 (42.5%)
615
628
605
232
35
156
219

(36.1%)
(5.5%)
(24.3%)
(34.1%)

thromboembolic risk. The intervention recommendation was
accepted in 353 patients (55.0%) and rejected in 289 patients
(45.0%).

Study Outcomes
Intervention acceptance. Acceptance and rejection groups differed significantly in terms of mean age (71.4 vs 74.1 years,
P ¼ .068), mean weight (88.9 vs 84.0 kg, P ¼ .0118), and mean
creatinine clearance (80.8 vs 71.0 ml/min, P ¼ .0040). Acceptance was more commonly observed for patients aged 20-64 (P
¼ .0137), patients on anticoagulant medications other than
warfarin (P < .0001), and in patients undergoing procedures
or surgeries with high bleeding risk (P ¼ .0068). Creatinine
level, gender, clopidogrel prescription, and thromboembolic
risk were similar between the acceptance and rejection groups.

Postoperative ED Visit
106 (16.5%)
536 (83.5%)
25 (3.9%)
617 (96.1%)
41 (6.4%)
268 (41.7%)
333 (51.9%)
276 (43%)
261 (40.7%)
105 (16.4%)
353 (55.0%)
289 (45.0%)

compared with pooled t tests, and categorical variables were
compared with w2 tests. Logistic regression was performed to
further analyze the association between baseline or clinical
parameters and primary outcome. Statistical analyses were
conducted using SAS Version 9.4 (SAS Institute Inc). A P
value of <.05 was considered statistically significant.

Results
Patient Population
The study sample consisted of 642 patients receiving chronic
OAC treatment who underwent elective procedures or surgeries from January 1, 2018, through January 31, 2019. Overall, patients had a mean age of 72.6 + 12.6 years, mean weight
of 86.7 + 24.1 kg, and mean creatinine of 1.23 mg/dL and
were predominantly male (n ¼ 369 [57.5%]; Table 1). In total,
76.8% of patients were older than 65 years. Warfarin (36.1%)
and apixaban (34.1%) were the most commonly used OAC
medications, and antiplatelet agents (aspirin, clopidogrel) were
used in less than 25% of the population sample. Approximately
half of the cohort underwent high bleeding risk procedures or
surgeries (51.9%), and 16.4% were considered at high

Overall, 38 (5.9%) of patients had at least 1 ED visit within 30
days of the surgery. Acceptance of MAPPP app recommendation was significantly associated with fewer ED visits (acceptance group: 4.0% vs rejection group: 8.3%, P ¼ .0205; Table
2). In contrast, male gender (P ¼ .0154) and age 80 years (P
¼ .0269) were associated with more ED visits (Table 3). Mean
age, mean weight, creatinine, creatinine clearance, procedural
bleeding risk, patient-related thromboembolic risk, and anticoagulation and antiplatelet medication usage were similar
between patients who went to the ED and those who did not.
In the logistic regression model, intervention acceptance
(odds ratio [OR]: 0.497, 95% CI: 0.249-0.992) and female
gender (OR: 0.401, 95% CI: 0.185-0.869) were significantly
associated with fewer 30-day ED visits, while advanced age
(age 80, OR: 2.116, 95% CI: 1.083-4.137) was associated
with more ED visits (Table 4). The overall predictive ability
of the model had a concordance index (c-index) of 0.681.

Discussion
Our prospective study evaluated the integration of the MAPPP
app as a CDS tool in the management of patients on chronic
OAC undergoing elective invasive procedures or surgeries.
Although the acceptance group and rejection group cohorts
differed in terms of kidney function, age, weight, medication
profile, and procedural bleeding risk, the acceptance group had
significantly fewer postoperative ED visits within 30 days.
Regression analysis revealed that intervention acceptance of
the MAPPP app recommendations (in addition to female sex)
was significantly associated with fewer ED visits and advanced
age ( 80 years) was associated with more ED visits.
The 30-day postoperative period, utilized in our study, has
been classically used in the evaluation of postoperative mortality and hospitalization.11-14 The primary outcome of postprocedural ED visits represents an important health care
economic burden and an outcome associated with the quality
of treatment.15-17 Theoretically, interventions that improve the
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Table 2. Intervention Group Characteristics and Outcomes (N ¼
642).a,b
Patient characteristics

Acceptance
(n ¼ 353)

Age category
20-64
96 (64.4%)
65-79
157 (54.5%)
80þ
100 (48.8%)
Gender
Male
201 (54.5%)
Female
152 (55.7%)
Weight (kg)
88.9 (25.4)
Creatinine (mg/dL)
1.27 (1.63)
Creatinine clearance (mL/min) 80.8 (46.5)
Anticoagulation medication
Warfarin
96 (41.4%)
Dabigatran
18 (51.4%)
Rivaroxaban
92 (59.0%)
Apixaban
147 (67.1%)
Warfarin
Yes
96 (41.4%)
No
257 (62.3%)
Antiplatelet medication
Aspirin
Yes
49 (46.2%)
No
304 (56.7%)
Clopidogrel
Yes
10 (40.0%)
No
343 (55.6%)
Procedure bleeding risk
Minimal
14 (34.1%)
Low
142 (53%)
High
197 (59.2%)
Patient’s thromboembolic risk
Low
155 (56.2 %)
Medium
142 (54.4 %)
High
56 (53.3%)
Outcome (30 days after surgery)
ED visit
Yes
14 (4.0%)
No
339 (96.0%)

Rejection
(n ¼ 289)

P value
.0137

53 (35.6%)
131 (45.5%)
105 (51.2%)
.7614
168 (45.5%)
121 (44.3%)
84.0 (22.2)
1.18 (0.56)
71.0 (36.8)

.0118
.3610
.0040
<.0001

136 (58.6%)
17 (48.6%)
64 (41.0%)
72 (32.9%)
<.0001
136 (58.6%)
153 (37.3%)
.0473
57 (53.8%)
232 (43.3%)
.1245
15 (60.0%)
274 (44.4%)
.0068
27 (65.9%)
126 (47%)
136 (40.8%)
.8586
121 (43.8 %)
119 (45.6 %)
49 (46.7 %)
.0205

Table 3. Patient characteristics Versus ED Visit in 30 Days (N ¼
642).a
ED visit
(n ¼ 38)

Patient characteristics
Age category
20-64
65-79
80þ
Gender
Male
Female
Weight
Creatinine
Creatinine clearance
Anticoagulation medication
Warfarin
Dabigatran
Rivaroxaban
Apixaban
Warfarin
Yes
No
Antiplatelet medication
Aspirin
Yes
No
Clopidogrel
Yes
No
Procedure bleeding risk
Minimal
Low
High
Patient’s thromboembolic risk
Low
Medium
High
a

No visit
(n ¼ 604)

P value
.0269

9 (6.0%)
10 (3.5%)
19 (9.3%)

140 (94%)
278 (96.5%)
186 (90.7%)
.0154

29 (7.9%)
9 (3.3%)
82.4 (21.0)
1.18 (0.59)
71.6 (33.9)

340
264
86.9
1.23
76.7

(92.1%)
(96.7%)
(24.2)
(1.30)
(43.2)

18 (7.8%)
1 (2.9%)
12 (7.7%)
7 (3.2%)

214
34
144
212

(92.2%)
(97.1%)
(92.3%)
(96.8%)

18 (7.8%)
20 (4.9%)

214 (92.2%)
390 (95.1%)

8 (7.6%)
30 (5.6%)

98 (92.4%)
506 (94.4%)

2 (8.0%)
36 (5.8%)

23 (92.0%)
581 (94.2%)

1 (2.4%)
18 (6.7%)
19 (5.7%)

40 (97.6%)
250 (93.3%)
314 (94.3%)

14 (5.1%)
17 (6.5%)
7 (6.7%)

262 (94.9%)
244 (93.5%)
98 (93.3%)

.2616
.7978
.4825
.1220

.1373

.4369

.6529

.5420

.7312

A P value of <.05 was considered statistically significant.

24 (8.3%)
265 (91.7%)

Abbreviation: ED, emergency department.
a
A P value of <.05 was considered statistically significant.
b
Values are mean (SD) or n (%).

quality of care should result in a decreased ADE incidence and
reduced ED visits and formed the basis of our hypothesis that
the MAPPP app would be effective in reducing ED visits during the 30-day postprocedural period. Emergency department
visits were decreased by approximately 50% in the acceptance
group versus the rejection group (4.0% vs 8.3%, P ¼ .0205).
Previously, the MAPPP mobile app version in 2016 was associated with a 20% relative reduction in the 30-day postoperative ADE rate, although the observed effect could not be
attributed directly to the app.10
Perioperative management of patients on chronic OAC in
elective periprocedural settings continues to be a complex
issue, as DOACs have emerged as alternative agents to warfarin with increased use in the treatment of patients with AF

Table 4. Logistic Regression Results of 30-Day ED Visit on Patient
Characteristics (N ¼ 642).a,b
Patient characteristics
Intervention acceptance
Age 80þ
Female gender
High bleeding risk
High thromboembolic risk
Aspirin

MLE
0.699
0.750
0.914
0.050
0.144
0.109

OR (95% CI)
0.497
2.116
0.401
0.951
1.155
1.115

(0.249-0.992)
(1.083-4.137)
(0.185-0.869)
(0.481-1.883)
(0.477-2.793)
(0.486-2.555)

P value
.0473
.0284
.0206
.8861
.7499
.7972

Abbreviations: MLE, maximal likelihood estimation; OR, odds ratio.
a
A P value of <.05 was considered statistically significant.
b
C-index ¼ 0.681.

and with established thromboembolic disease.18 Although the
temporary perioperative interruption of DOACs has been associated with low rates of perioperative thrombotic events, the
lack of awareness of appropriate management options may lead
to severe postoperative complications. 2,19 Despite the
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evidence-based benefit of DOACs in the treatment of thromboembolism and AF, physicians and nurse practitioners
involved in the management of anticoagulation are not always
familiar with the most recent advances and recommendations.10 Our study’s acceptance group had better renal function
(creatinine clearance: 80.8 vs 71.0 mL/min, P ¼ .0040) compared to the rejection group. In addition, acceptance of MAPPP
app recommendations was higher in patients receiving OAC
medications other than warfarin (P < .0001). These findings
suggest that MAPPP app end users preferred to follow their
clinical judgment, instead of the most current guidelines in
patients on chronic OAC with impaired renal function
(increased ADE risk) and in patients receiving warfarin, which
has been in the market for many years and with which health
care providers are very familiar. Nonfamiliarity regarding
emerging data about the safety and efficacy of DOACs in periprocedural settings may have played a role in greater adherence
to the evidence-based recommendations for periprocedural
DOAC management as incorporated into the MAPPP app.
The usual distribution of guidelines through hard or electronic copies is a passive user-dependent education process.
In contrast, mobile and web-based apps have been shown to
be effective CDS and guideline dissemination tools.10,20,21
The MAPPP app development has been previously described
and its objective was to reduce the rate of anticoagulantassociated ADEs.10 Benefits include broad dissemination,
remote updates according to newer guidelines, and tracking
of utilization. Notably, the American College of Cardiology
(ManageAnticoag app) and University of Michigan (MAQI2
Anticoagulation Toolkit) have developed apps similar to the
MAPPP app in order to facilitate appropriate periprocedural
anticoagulation management.22,23 The EHR-integrated CDS
tools have been assessed in a variety of settings with patients
receiving anticoagulant medications. Ahuja et al developed a
CDS tool to provide evidence-based dosing and increase the
safety of DOACs in hospitalized patients. User adherence to
CDS recommendations was high (75-87%), and noncompliance/lower dosing was mainly attributed to impaired renal
function, history of bleeding, and perceived patients’ vulnerability.24 A recent systematic review assessed the EHR interventions that could potentially improve the safety of inpatient
anticoagulation. Only 5 of 27 studies evaluated the CDS tool
impact in terms of morbidity, mortality, and hospital
readmissions.25
Our study provides further evidence on the value of integrating the MAPPP app into additional hospital EHRs and
measuring outcomes as part of patient safety goals. The perioperative management of anticoagulation is included as a new
Improvement Activity in the Medicare Quality Payment program and additionally is a new requirement for Joint Commission National Patient Safety Goals (NPSG.03.05.01) for the
Hospital Accreditation Program. We anticipate an increase in
MAPPP app utilization and EHR integration due to recent recognition by the Joint Commission 2019 National Patient Safety
Goals, which recommended education and approved protocols
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for the initiation and maintenance of anticoagulation regimens,
including the during periprocedural period.26
Several limitations to our study should be acknowledged.
The MAPPP app generalizability is limited by the population
characteristics (adult patients with creatinine clearance 15
mL/min) and the ability of the EHR to incorporate MAPPP
in the form of a fully Substitutable Medical Applications and
Reusable Technologies on Fast Healthcare Interoperability
Resources (SMART on FHIR) application. Further, our app
was designed with the ability to use the latest SMART on FHIR
technology to allow seamless and rapid interaction with EHRs,
but the health systems were not ready for this level of integration. Another limitation of our study is its relatively small
sample size and the possibility of hidden confounders between
the acceptance and rejection groups, which could potentially
affect the study power and identification of any association
between primary outcome and investigated variables.

Conclusion
Integration of a CDS tool for the management of patients on
chronic OAC undergoing elective procedures or surgeries—the
MAPPP app—into an EHR was associated with a significantly
lower rate of ED visits during the 30-day postoperative period.
The MAPPP app as part of HIT is a promising evidence-based
CDS tool that can augment clinical management and has the
potential to decrease anticoagulation-related adverse outcomes.
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